Page 80 - Read Online

Page 810 Tucker et al. Cancer Drug Resist 2019;2:803-12 I http://dx.doi.org/10.20517/cdr.2019.09

Supervised the work: Chesler L

Availability of data and materials
Not applicable.

Financial support and sponsorship
The authors are supported by a programme grant from Cancer Research UK (C34648/A18339 and C34648/
A14610).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Morgenstern, DA, Potschger U, Moreno L, Papadakis V, Owens C, et al. Risk stratification of high-risk metastatic neuroblastoma: a
report from the HR-NBL-1/SIOPEN study. Pediatr Blood Cancer 2018;65:e27363.
2. Bresler, SC, Weiser DA, Huwe PJ, Park JH, Krytska K, et al. ALK mutations confer differential oncogenic activation and sensitivity to
ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682-94.
3. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation
spectrum in tumors with MYCN amplification. Clin Cancer Res 2010;16:4353-62.
4. Basta, NO, Halliday GC, Makin G, Birch J, Feltbower R, et al. Factors associated with recurrence and survival length following
relapse in patients with neuroblastoma. Br J Cancer 2016;115:1048-57.
5. Barone G, Anderson J, Pearson AD, Petrie K, Chesler L. New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK.
Clin Cancer Res 2013;19:5814-21.
6. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein
and blocks malignant progression in neuroblastoma. Cancer Res 2006;66: 8139-46.
7. Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, et al. Inhibition of mTOR-kinase destabilizes MYCN and is a potential
therapy for MYCN-dependent tumors. Oncotarget 2016;7:57525-44.
8. Smith JR, Moreno L, Heaton SP, Chesler L, Pearson AD, et al. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/
AKT/mTOR pathway signaling in children with neuroblastoma. Mol Oncol 2016;10:538-52.
9. Buchel G, Carstensen A, Mak KY, Roeschert I, Leen E, et al. Association with aurora-A controls N-MYC-dependent promoter escape
and pause release of RNA polymerase II during the cell cycle. Cell Rep 2017; 21:3483-97.
10. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, et al. Small molecule inhibitors of aurora-a induce proteasomal
degradation of N-myc in childhood neuroblastoma. Cancer Cell 2013;24:75-89.
11. Gustafson WC, Meyerowitz JC, Nekritz EA, Chen J, Benes C, et al. Drugging MYCN through an allosteric transition in Aurora kinase
A. Cancer Cell 2014;26:414-27.
12. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, et al. Stabilization of N-Myc is a critical function of Aurora A in human
neuroblastoma. Cancer Cell 2009;15:67-78.
13. DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, et al. Phase I study of the aurora A kinase inhibitor alisertib in combination
with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma
therapy) trial. J Clin Oncol 2016;34:1368-75.
14. DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, et al. Phase II trial of alisertib in combination with irinotecan and temozolomide
for patients with relapsed or refractory neuroblastoma. Clin Cancer Res 2018; 24:6142-9.
15. Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, et al. Accelerating drug development for neuroblastoma - new drug
development strategy: an innovative therapies for children with cancer, European network for cancer research in children and
adolescents and international society of paediatric oncology Europe neuroblastoma project. Expert Opin Drug Discov 2017;12:801-11.
16. Mosse YP, Fox E, Teachey DT, Reid JM, Safgren SL, et al. A phase II study of alisertib in children with recurrent/refractory solid